Media Centre

MSD abides by Medicines Australia’s Code of Conduct and the Therapeutic Goods Act.​

​Both prohibit a pharmaceutical company from direct to consumer advertising which includes issuing public press statements about our prescription medicines. We are able to issue public statements to advise registration of a new medicine, a reimbursement notice of a new medicine or any general corporate news not related to our medicines. For any specific issues please contact the Communications Manager.

Latest news:

Australians battling a form of cancer which has seen no improvement in survival rates in the past 30 years 2 may now be eligible for Pharmaceutical Benefits Scheme subsidised access to a medicine that activates the body’s immune system to detect and attack tumour cells.1,3More

28/10/18: Government subsidy for KEYTRUDA ® (pembrolizumab) to help fight Australia’s leading cause of cancer death 1,2

MSD is committed to providing access to KEYTRUDA for eligible lung cancer patients. Today marks a crucial first step in providing reimbursed immunotherapy as a first-line treatment for thousands of eligible Australians battling a type of advanced. More

MSD Australia welcomes the Pharmaceutical Benefits Advisory Committee’s (PBAC) consideration of proposals to subsidise immuno-oncology (IO) medicines across multiple tumour types for Australian cancer patients at a Special Meeting being held today. More

MSD Australia today acknowledged the work being undertaken by Federal Health Minister, The Hon Greg Hunt MP to drive increased access to immuno-oncology (IO) medicines through a multi-cancer approach and urged the government to commit appropriate funds. More

21/02/18: Third year running - MSD recognised as Employer of Choice for Gender Equality

Australia’s Workplace Gender Equality Agency (WGEA) has today recognised MSD, a leading biopharmaceutical company, as an Employer of Choice for Gender Equality (EOCGE). More

Australians with advanced lung cancer are unlikely to survive longer than two years after they commence treatment, according to new research which has highlighted the limitations of chemotherapy as a front-line defence against the nation’s leading cancer killer more

MSD today welcomed the Treasurer’s announcement that a new fund will be created to invest in innovative new medicines more

30/01/2017: Report shows more work is needed in fight against cardiovascular disease

MSD today welcomed many of the recommendations proposed in a report made public by the Department of Health as part of a Post-market Review into MSD’s cholesterol lowering medicine Ezetimibe (the product). more

25/01/2017: ‘Head in the sand’ attitude may put hearts at risk – new research

New research reveals that ageing Australians consider themselves thinner, fitter and healthier than they actually are, placing many in the firing line for life-threatening heart attack and stroke. more

18/01/2017: MSD welcomes new Minister for Health

MSD today welcomed the Prime Minister’s announcement that the Hon. Greg Hunt will be taking over as the Minister for Health, and Minister for Sport. more

05/11/2015: MSD awarded Employer of Choice for Gender Equality

The Workplace Gender Equality Agency (WGEA) has today awarded MSD the Employer of Choice for Gender Equality citation for 2015. more

24/06/2015: MSD and One Disease Announce $1.2 Million to Improve Indigenous Life Expectancy

The goal of closing the life-expectancy gap between Indigenous and non-Indigenous Australians is now one-step closer thanks to a $1.2 million donation to the cause today. MSD in Australia, a subsidiary of Merck & Co. Inc. donated $600,000 to not-for-profit organisation One Disease, which is also being matched dollar-for-dollar by an unnamed benefactor... more

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.